Peak Bio, Inc. is a biopharmaceutical company based in Pleasanton, CA, dedicated to developing innovative therapies for patients with complex medical conditions. With a focus on inflammatory, rare and specialty diseases, as well as cancer, Peak Bio aims to address significant unmet medical needs. Led by an experienced management team with over 50 years of industry expertise, the company specializes in small molecules, antibodies, and antibody-drug-conjugates (ADCs) for drug development, creating best-in-class therapeutics.
One of Peak Bio's key areas of research is inflammation, where they are investigating PHP-303, a novel small molecule inhibitor of Neutrophil Elastase. This compound shows promise as a therapeutic option for a rare and potentially life-threatening genetic condition called AATD. In the field of oncology, Peak Bio focuses on developing ADCs, which combine the selectivity of monoclonal antibodies with the cytotoxic potential of small molecule therapeutics, offering targeted anti-cancer treatments. With a commitment to advancing medical science, Peak Bio is dedicated to improving the lives of patients through innovative therapies.
Generated from the website